BTIG analyst Julian Harrison has maintained their bullish stance on ORKA stock, giving a Buy rating on September 28.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Julian Harrison has given his Buy rating due to a combination of factors that highlight Oruka Therapeutics’ promising future prospects. The company’s lead candidate, ORKA-002, is expected to significantly enhance the company’s stock value, particularly with its Phase 1 data anticipated by the end of 2025. ORKA-002’s potential lies in its extended half-life, which could offer substantial improvements over existing treatments like Bimzelx, allowing for less frequent dosing and potentially better patient compliance.
Furthermore, Oruka’s strategic focus on expanding ORKA-002’s application beyond its initial indication of psoriasis to other conditions such as psoriatic arthritis and hidradenitis suppurativa presents additional growth opportunities. The successful trajectory of similar drugs like Bimzelx, which has seen substantial market growth, provides a positive outlook for ORKA-002. This combination of innovative product development and market potential underpins Harrison’s optimistic Buy rating for Oruka Therapeutics.
According to TipRanks, Harrison is a 5-star analyst with an average return of 26.5% and a 49.83% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Oruka Therapeutics, United Therapeutics, and Nektar Therapeutics.
In another report released on September 28, Leerink Partners also reiterated a Buy rating on the stock with a $44.00 price target.